A. Wallin

K. Blennow, L. Minthon, N. Bogdanovic, 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Current definition and classification of dementia diseases

A. Wallin, 1996, Acta neurologica Scandinavica. Supplementum.

Parenteral administration of GM1 ganglioside to presenile Alzheimer patients

K. Blennow, A. Wallin, J. Månsson, 1990, Acta neurologica Scandinavica.

Lack of Efficacy of Vinpocetine in Vascular Dementia

K. Blennow, A. Wallin, A. Nyth, 1990 .

Longitudinal measurements of cerebrospinal fluid biomarkers over four years in mild cognitive impairment

K. Blennow, H. Zetterberg, S. Rolstad, 2012, Alzheimer's & Dementia.

[Harmonization of dementia diagnoses--a necessary quality assurance].

L. Wahlund, A. Wallin, U. Passant, 2001, Läkartidningen.

Consensus guidelines for lumbar puncture in patients with neurological diseases

Bernhard Hemmer, Pedro Rosa-Neto, Jakub Hort, 2017, Alzheimer's & dementia.

Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks

F. Barkhof, G. Frisoni, P. Visser, 2022, Frontiers in Aging Neuroscience.

Nimodipine in subcortical vascular dementia trial.

T. del Ser, L. Pantoni, D. Inzitari, 1999, Alzheimer disease and associated disorders.

Heterogeneity of the Course of Alzheimer's Disease: A Differentiation of Subgroups

K. Blennow, A. Wallin, G. Bråne, 1991 .

Vitamin B12 in CSF: reduced CSF/serum B12 ratio in demented men

K. Blennow, A. Wallin, B. Regland, 1992, Acta neurologica Scandinavica.

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

K. Blennow, P. Scheltens, M. Leon, 2014, Alzheimer's & Dementia.

Apathy is a prominent neuropsychiatric feature of radiological white‐matter changes in patients with dementia

M. Jonsson, K. Lind, Å. Edman, 2009, International journal of geriatric psychiatry.

Relationship between depressive symptomatology and the subcortical brain syndrome in dementia

K. Lind, Å. Edman, M. Sjögren, 2002, International journal of geriatric psychiatry.

Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

R. Dobson, K. Blennow, J. Molinuevo, 2019, bioRxiv.

Treatment of Alzheimer’s Disease with Clioquinol

K. Blennow, M. Jonsson, M. Sjögren, 2001, Dementia and Geriatric Cognitive Disorders.

The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2001, Dementia and Geriatric Cognitive Disorders.

Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease

K. Blennow, O. Hansson, H. Zetterberg, 2013, Psychoneuroendocrinology.

Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.

Anders Wallin, Henrik Zetterberg, Kaj Blennow, 2009, Journal of Alzheimer's disease : JAD.

Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18–88 years of age

K. Blennow, A. Wallin, I. Skoog, 1993, European Neuropsychopharmacology.

Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease

K. Blennow, A. Wallin, I. Skoog, 1992, Neurobiology of Aging.

A double‐blind evaluation of electroconvulsive therapy in Parkinson's disease with “on‐off” phenomena

A. Wallin, J. Balldin, L. Svennerholm, 1987, Acta neurologica Scandinavica.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

D. Rujescu, K. Blennow, H. Hampel, 2014, JAMA psychiatry.

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2007, Journal of Alzheimer's disease : JAD.

VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue afflicted by alzheimer's disease/senile dementia of the Alzheimer type

A. Wallin, T. Bártfai, C. Gottfries, 1988, Neurobiology of Aging.

Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes

B. V. van Bon, R. Pfundt, B. D. de Vries, 2010, Journal of Medical Genetics.

Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract

K. Blennow, L. Minthon, N. Bogdanovic, 2010, Mechanisms of Ageing and Development.

Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia

A. Nordlund, J. Svensson, A. Wallin, 2017, Psychoneuroendocrinology.

Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease

K. Blennow, O. Hansson, H. Zetterberg, 2013, Psychoneuroendocrinology.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

K. Blennow, L. Kappos, P. Visser, 2019, JAMA neurology.

Hyperactivity in the hypothalamic-pituitary-adrenal axis in demented patients with delirium

K. Blennow, Å. Edman, A. Wallin, 2001, International clinical psychopharmacology.

Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases

K. Blennow, O. Hansson, H. Zetterberg, 2010, Front. Ag. Neurosci..

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

Magda Tsolaki, Giovanni B. Frisoni, Min Kim, 2019, Alzheimer's & dementia.

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease

Johan Svensson, Anders Wallin, Henrik Zetterberg, 2016, Dementia and Geriatric Cognitive Disorders Extra.

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

K. Blennow, E. Vanmechelen, H. Zetterberg, 2009, Neuroscience Letters.

Low frequency of post‐lumbar puncture headache in demented patients

A. Wallin, B. K., O. Häger, 1993, Acta neurologica Scandinavica.

Neurotransmitter deficits in a non‐multi‐infarct category of vascular dementia

B. Winblad, I. Alafuzoff, A. Carlsson, 1989, Acta neurologica Scandinavica.

phenotypes microduplications that show distinctive co-locating 17 p 13 . 3 microdeletions and Further molecular and clinical delineation of

R. Pfundt, C. Martin, A. Wallin, 2022 .

CSF amyloid β42 and tau levels correlate with AIDS dementia complex

K. Blennow, A. Wallin, B. Brew, 2005, Neurology.

CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.

K. Blennow, A. Wallin, B. Brew, 2005, Neurology.

Blood‐brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors

I Karlsson, K. Blennow, A. Wallin, 1990, Acta neurologica Scandinavica.

Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study

K. Blennow, O. Hansson, S. Movérare-Skrtic, 2012, Experimental Gerontology.

Aggrecan and chondroitin-6-sulfate abnormalities in schizophrenia and bipolar disorder: a postmortem study on the amygdala

S. Berretta, A. Wallin, B. Caterson, 2015, Translational Psychiatry.

Local and systemic GM‐CSF increase in Alzheimer's disease and vascular dementia

K. Blennow, A. Wallin, A. Tarkowski, 2001, Acta neurologica Scandinavica.

Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients

K. Blennow, J. Svensson, A. Wallin, 2019, Scientific Reports.

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies

F. Barkhof, G. Frisoni, P. Visser, 2021, Frontiers in Aging Neuroscience.

Replication study of plasma proteins relating to Alzheimer's pathology

K. Blennow, J. Molinuevo, P. Scheltens, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia

K. Blennow, A. Wallin, A. Tarkowski, 1999, Journal of Clinical Immunology.

Intrathecal Release of Nitric Oxide in Alzheimer’s Disease and Vascular Dementia

K. Blennow, A. Wallin, Å. Wennmalm, 2000, Dementia and Geriatric Cognitive Disorders.

Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.

K. Blennow, R. Deane, H. Zetterberg, 2011, Journal of Alzheimer's disease : JAD.

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Anders Wallin, Björn Holmberg, Annika Olsson, 2005, Clinical chemistry.

Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma

K. Blennow, H. Vanderstichele, L. Minthon, 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

K. Blennow, C. Spenger, E. Vanmechelen, 1995, Molecular and chemical neuropathology.

Neurofilament protein in cerebrospinal fluid: A marker of white matter changes

K. Blennow, M. Jonsson, K. Lind, 2001, Journal of neuroscience research.

High White Matter Lesion Load Is Associated with Hippocampal Atrophy in Mild Cognitive Impairment

M. Jonsson, Å. Edman, M. Göthlin, 2011, Dementia and Geriatric Cognitive Disorders.

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

K. Blennow, T. Fladby, H. Zetterberg, 2009, Multiple sclerosis.

Heterogeneity of Vascular Dementia: Mechanisms and Subgroups

K. Blennow, A. Wallin, 1993, Journal of geriatric psychiatry and neurology.

Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy

K. Blennow, L. Pantoni, D. Inzitari, 2014, Dementia and Geriatric Cognitive Disorders Extra.

Both total and phosphorylated tau are increased in Alzheimer's disease

K. Blennow, H. Vanderstichele, M. Tullberg, 2001, Journal of neurology, neurosurgery, and psychiatry.

Increased Saliva Cortisol Awakening Response in Patients with Mild Cognitive Impairment

T. Olsson, A. Nordlund, K. Lind, 2007, Dementia and Geriatric Cognitive Disorders.

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease

K. Blennow, D. Prvulovic, H. Hampel, 2011, Molecular Neurodegeneration.

Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.

K. Blennow, L. Minthon, O. Hansson, 2007, International journal of molecular medicine.

Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

W. K. Cullen, R. Anwyl, M. Rowan, 2008, The Journal of Neuroscience.

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

K. Zahs, K. Blennow, K. Ashe, 2013, JAMA neurology.

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

K. Blennow, W. Honer, L. Frölich, 2014, Molecular Neurodegeneration.

Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer’s Disease Dementia in Individuals With Mild Cognitive Impairment

D. Rujescu, K. Blennow, H. Hampel, 2017, Biological Psychiatry.

Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer’s disease

K. Blennow, P. Lewczuk, J. Wiltfang, 2005, Experimental Brain Research.

Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

K. Blennow, H. Vanderstichele, E. Vanmechelen, 1998 .

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

K. Blennow, L. Minthon, M. Sjögren, 2000, Neurology.

Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia

Anders Wallin, Kaj Blennow, Andrej Tarkowski, 2002, Neurobiology of Aging.

Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.

K. Blennow, C. Blomstrand, A. Wallin, 1997, Dementia and geriatric cognitive disorders.

Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN‐derived networks and highlights causal links in Alzheimer's disease

F. Barkhof, G. Frisoni, P. Visser, 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2005, Dementia and Geriatric Cognitive Disorders.

No Association of VEGF Polymorphims with Alzheimer’s Disease

K. Blennow, L. Minthon, H. Zetterberg, 2010, NeuroMolecular Medicine.

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease

K. Blennow, O. Hansson, H. Zetterberg, 2013, PloS one.

Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42

A. Wallin, V. Stenset, T. Fladby, 2006, Neurology.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort

K. Blennow, J. Molinuevo, P. Scheltens, 2019, Alzheimer's & Dementia.

The Overlap between Alzheimer’s Disease and Vascular Dementia: The Role of White Matter Changes

A. Wallin, 1998, Dementia and Geriatric Cognitive Disorders.

Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production.

K. Blennow, A. Wallin, I. Skoog, 1993, European neurology.

A novel ARC gene polymorphism is associated with reduced risk of Alzheimer’s disease

K. Blennow, L. Minthon, N. Bogdanovic, 2012, Journal of Neural Transmission.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

D. Y. Lee, A. Fagan, J. Morris, 2017, Alzheimer's & Dementia.

Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort

K. Blennow, J. Molinuevo, P. Scheltens, 2021, Biomedicines.

Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?

L. Parnetti, A. Wallin, F. Amenta, 2001, Mechanisms of Ageing and Development.

Cystatin C in cerebrospinal fluid and multiple sclerosis

Anders Wallin, Henrik Zetterberg, Kaj Blennow, 2007, Annals of neurology.

Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment.

K. Blennow, H. Zetterberg, S. Rolstad, 2012, Journal of Alzheimer's disease : JAD.

Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.

K. Blennow, H. Zetterberg, M. Bjerke, 2011, Journal of Alzheimer's disease : JAD.

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

K. Blennow, P. Scheltens, H. Hampel, 2007, Neurology.

An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid

Anders Wallin, Henrik Zetterberg, Kaj Blennow, 2006, Neuroscience Letters.

High frequency of cognitive dysfunction before stroke among older people

A. Nordlund, A. Wallin, E. Tarkowski, 2011, International journal of geriatric psychiatry.

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

K. Blennow, S. Santi, L. Mosconi, 2009, Neurobiology of Aging.

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.

K. Blennow, H. Rusinek, S. de Santi, 2009, Journal of Alzheimer's disease : JAD.

B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia

Michael Fu, Daniel Kondziella, Anders Wallin, 2009, Neuroreport.

Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease.

K. Blennow, H. Zetterberg, J. Svensson, 2020, Journal of Alzheimer's disease : JAD.

Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment

K. Blennow, H. Zetterberg, J. Svensson, 2017, PloS one.

Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype

K. Blennow, L. Minthon, Å. Edman, 2001, Journal of Neural Transmission.

CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

K. Blennow, H. Vanderstichele, L. Minthon, 2000, Journal of Neural Transmission.

Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment

K. Blennow, H. Vanderstichele, P. Lewczuk, 2009 .

A population study on blood-brain barrier function in 85-year-olds

K. Blennow, A. Wallin, I. Skoog, 1998, Neurology.

Symptoms, Vascular Risk Factors and Blood-Brain Barrier Function in Relation to CT White-Matter Changes in Dementia

K. Blennow, Å. Edman, M. Sjögren, 2000, European Neurology.

Formulas for the quantitation of intrathecal IgG production Their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis

K. Blennow, A. Wallin, T. Pirttilä, 1994, Journal of the Neurological Sciences.

Biochemical substrates in normal aging and Alzheimer's disease.

A. Wallin, C. Gottfries, 1990, Pharmacopsychiatry.

Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.

K. Blennow, Å. Edman, H. Zetterberg, 2011, Journal of Alzheimer's disease : JAD.

Monoamine Metabolites in Cerebrospinal Fluid and Behavioral Ratings in Patients with Early and Late Onset of Alzheimer Dementia

K. Blennow, L. Parnetti, A. Wallin, 1989, Alzheimer disease and associated disorders.

Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease

K. Blennow, B. de Strooper, R. Vandenberghe, 2013, Neurology.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease

K. Blennow, L. Minthon, O. Hansson, 2016, Journal of Alzheimer's disease : JAD.

Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer’s disease

J. Svensson, A. Wallin, Alexandra Horvath, 2019, Psychoneuroendocrinology.

Pathogenetic basis of vascular dementia.

K. Blennow, A. Wallin, 1991, Alzheimer Disease and Associated Disorders.

White‐matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors

K. Blennow, A. Wallin, C. Gottfries, 1991, Acta neurologica Scandinavica.

Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility

K. Blennow, O. Hansson, H. Zetterberg, 2011, NeuroMolecular Medicine.

SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME

Å. Edman, M. Sjögren, A. Wallin, 1997, International Journal of Geriatric Psychiatry.

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

Philip S. Insel, K. Blennow, G. Frisoni, 2017, Alzheimer's Research & Therapy.

Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia

K. Blennow, M. Sjögren, A. Wallin, 2003, Dementia and Geriatric Cognitive Disorders.

Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease.

K. Blennow, H. Zetterberg, J. Svensson, 2015, Journal of Alzheimer's disease : JAD.

Diagnosis of dementias using partial least squares discriminant analysis.

J Gottfries, K. Blennow, A. Wallin, 1995, Dementia.

The Cognitive Assessment Battery (CAB): a rapid test of cognitive domains

Anders Wallin, Arto Nordlund, A. Nordlund, 2011, International Psychogeriatrics.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

K. Blennow, J. Molinuevo, P. Scheltens, 2019, Alzheimer's & Dementia.

Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting

C. Wattmo, E. Londos, L. Minthon, 2006, Dementia and Geriatric Cognitive Disorders.

No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression

K. Blennow, A. Brookes, L. Minthon, 2000, Journal of Neural Transmission.

Prevalence of dementia and regional brain syndromes in long-standing Parkinson's disease.

A. Wallin, C. Jennersjö, A. Granérus, 1999, Parkinsonism & related disorders.

Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study

K. Blennow, E. V. van Straaten, L. Pantoni, 2010, European journal of neurology.

Relationship between mental impairment and HPA axis activity in dementia disorders.

K. Blennow, A. Wallin, G. Bråne, 1994, Dementia.

Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

K. Blennow, E. Vanmechelen, M. Sjögren, 2002, Dementia and Geriatric Cognitive Disorders.

Depressive symptoms and white matter changes in patients with dementia

M. Jonsson, K. Lind, Å. Edman, 2006, International journal of geriatric psychiatry.

Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial

L. Pantoni, D. Inzitari, T. Erkinjuntti, 2000, Journal of the Neurological Sciences.

Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia.

K. Blennow, A. Wallin, L. Rosengren, 1996, Dementia.

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

K. Blennow, O. Hansson, H. Zetterberg, 2011, Journal of Alzheimer's disease : JAD.

[A consensus on dementia diseases (I): Classification and investigation].

A. Wallin, 1990, Lakartidningen.

Frontotemporal Dementia Can Be Distinguished from Alzheimer’s Disease and Subcortical White Matter Dementia by an Anterior-to-Posterior rCBF-SPET Ratio

Anders Wallin, Carsten Wikkelsö, M. Sjögren, 2000, Dementia and Geriatric Cognitive Disorders.

Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease

A. Öhrfelt, M. Bjerke, A. Wallin, 2012, Journal of the Neurological Sciences.

Amyloid β1–40 Quantification in CSF: Comparison between Chromatographic and Immunochemical Methods

K. Blennow, G. Waldemar, H. Zetterberg, 2007, Dementia and Geriatric Cognitive Disorders.

Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment

Anders Wallin, Annika Olsson, Kaj Blennow, 2005 .

Amino-Truncated-Amyloid 42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2005 .

Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases

K. Blennow, L. Minthon, N. Bogdanovic, 2010, NeuroMolecular Medicine.

White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia – diagnostic and pathogenetic aspects

K. Blennow, A. Wallin, G. Långström, 1989, Acta neurologica Scandinavica.

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data

J. Molinuevo, P. Visser, M. Tsolaki, 2018, Front. Aging Neurosci..

The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

K. Blennow, A. Wallin, M. Landén, 1996, Journal of neurology, neurosurgery, and psychiatry.

Converging pathways of chromogranin and amyloid metabolism in the brain.

K. Blennow, O. Hansson, H. Zetterberg, 2010, Journal of Alzheimer's disease : JAD.

Potential Biological Markers for Cerebrovascular Disease

A. Kurz, M. Riemenschneider, A. Wallin, 2003, International Psychogeriatrics.

Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease

K. Blennow, M. Tullberg, P. Hellström, 2022, Frontiers in Neurology.

caused by heading in soccer No neurochemical evidence for brain injury

K. Blennow, M. Jonsson, H. Zetterberg, 2007 .

Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia.

M. Jonsson, J. Svensson, M. Bjerke, 2021, Journal of Alzheimer's disease : JAD.

Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment

Jan Komorowski, Anders Wallin, Henrik Zetterberg, 2012, Journal of Neural Transmission.

Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia

M. Sjögren, A. Wallin, 2001, Mechanisms of Ageing and Development.

Objective Measurement of the Alertness Level in Dementia

M. Matousek, Å. Edman, M. Sjögren, 2003, Dementia and Geriatric Cognitive Disorders.

Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease

K. Blennow, H. Zetterberg, J. Svensson, 2015, Neuroscience Letters.

Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.

K. Blennow, H. Zetterberg, J. Svensson, 2017, Journal of Alzheimer's Disease.

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

R. Dobson, J. Molinuevo, P. Scheltens, 2018, Alzheimer's Research & Therapy.

Sex-specific metabolic pathways associate with Alzheimer's Disease (AD) endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery (EMIF-AD MBD) cohort

K. Blennow, J. Molinuevo, P. Scheltens, 2021, medRxiv.

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology

R. Dobson, K. Blennow, J. Molinuevo, 2020, Journal of Alzheimer's disease : JAD.

Reduced CSF CART in dementia with Lewy bodies

C. Nilsson, A. Wallin, B. B. Andersen, 2009, Neuroscience Letters.

Decreased monoamine metabolites in frontotemporal dementia and Alzheimer’s disease

K. Blennow, L. Minthon, M. Sjögren, 1998, Neurobiology of Aging.

Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease

K. Blennow, L. Minthon, H. Zetterberg, 2010, Molecular Neurodegeneration.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE-ε4

Nick C Fox, K. Blennow, J. Schott, 2013, Alzheimer's & Dementia.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4

K. Blennow, J. Hardy, J. Schott, 2013, Molecular Psychiatry.

Heterogeneity in Alzheimer’s Disease: A European View

K. Blennow, A. Wallin, 1994 .

Decreased myelin lipids in Alzheimer's disease and vascular dementia

A. Wallin, I. Karlsson, L. Svennerholm, 1989, Acta neurologica Scandinavica.

Clinical subgroups of the Alzheimer syndrome

K. Blennow, A. Wallin, 1996, Acta neurologica Scandinavica. Supplementum.

Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions – The LADIS Study

K. Blennow, A. Gouw, L. Pantoni, 2012, Dementia and Geriatric Cognitive Disorders.

Altered blood‐brain‐barrier function in Alzheimer's disease?

K. Blennow, A. Wallin, T. Pirttilä, 1994, Acta neurologica Scandinavica.

Blood brain barrier function in vascular dementia

K. Blennow, A. Wallin, I. Karlsson, 1990, Acta neurologica Scandinavica.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Anders Wallin, Annika Olsson, Kaj Blennow, 2005, Clinical chemistry.

Progression from Mild to Pronounced MCI Is Not Associated with Cerebrospinal Fluid Biomarker Deviations

K. Blennow, A. Nordlund, K. Lind, 2011, Dementia and Geriatric Cognitive Disorders.

Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment

K. Blennow, Å. Edman, E. Olsson, 2010, Dementia and Geriatric Cognitive Disorders.

Subcortical symptoms predominate in vascular dementia

K. Blennow, A. Wallin, C. Gottfries, 1991 .

A β dimer-containing human cerebrospinal fluid disrupts synaptic plasticity : prevention by systemic passive immunization

W. K. Cullen, R. Anwyl, M. Rowan, 2009 .

Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier.

K. Blennow, A. Wallin, J. Chong, 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

Cognitive Reserve in Relation to Abeta42 in Patients Converting from MCI to Dementia – A Follow-Up Report

A. Wallin, A. Nordlund, H. Zetterberg, 2009, Dementia and Geriatric Cognitive Disorders.

Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of Concept

A. Wallin, A. Nordlund, H. Zetterberg, 2009, Dementia and Geriatric Cognitive Disorders.

Subtypes of vascular dementia.

A. Wallin, V. Hachinski, T. Erkinjuntti, 1999, Alzheimer disease and associated disorders.

Proteolytic Activity is Increased in Lymphocytes from Patients with Alzheimer’s Disease

K. Blomgren, K. Blennow, A. Wallin, 1997 .

Increased Proteolytic Activity in Erythrocytes from Patients with Alzheimer's Disease

K. Blennow, A. Wallin, C. Gottfries, 1992 .

S18Y polymorphism in Alzheimer's disease

K. Blennow, L. Minthon, H. Zetterberg, 2010 .

Clinical diagnosis of Alzheimer's disease by primary care physicians and specialists

K. Blennow, A. Wallin, 1992, Acta neurologica Scandinavica. Supplementum.

Comorbidity of other chronic age-dependent diseases in dementia

A. Wallin, L. Widman, J. Thorpe, 1994, Aging.

The neurochemistry of vascular dementia.

K. Blennow, A. Wallin, C. Gottfries, 1994, Dementia.

SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME

Å. Edman, M. Sjögren, A. Wallin, 1997, International journal of geriatric psychiatry.

P1-370 Monitoring the biochemical aftermath of boxing by cerebrospinal fluid analyses

K. Blennow, L. Wahlund, P. Mehta, 2006, Alzheimer's & Dementia.

Blood‐brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein‐β in patients with subcortical small‐vessel disease

K. Blennow, M. Jonsson, H. Zetterberg, 2022, Alzheimer's & dementia.

Subcortical ischaemic vascular dementia

H. Chui, L. Pantoni, T. Erkinjuntti, 2002, The Lancet Neurology.

Neurochemical substrates of human aging and dementia.

E. Mohr, A. Wallin, C. Carter, 1990, Pharmacopsychiatry.

Intra‐Blood-Brain‐Barrier Synthesis of Immunoglobulins in Patients with Dementia of the Alzheimer Type

K. Blennow, A. Wallin, P. Davidsson, 1990, Alzheimer Disease and Associated Disorders.

Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases

K. Blennow, O. Hansson, H. Zetterberg, 2010, Front. Ag. Neurosci..

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

K. Zahs, K. Blennow, K. Ashe, 2013, JAMA neurology.

Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer’s Disease Dementia in Individuals With Mild Cognitive Impairment

D. Rujescu, K. Blennow, H. Hampel, 2017, Biological Psychiatry.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

D. Y. Lee, A. Fagan, A. Fleisher, 2017, Alzheimer's & Dementia.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4

K. Merikangas, K. Blennow, H. Qin, 2013, Molecular Psychiatry.

Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.

K. Blennow, H. Zetterberg, M. Bjerke, 2011, Journal of Alzheimer's disease : JAD.

Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease

K. Blennow, B. de Strooper, R. Vandenberghe, 2013, Neurology.

High education may offer protection against tauopathy in patients with mild cognitive impairment.

K. Blennow, A. Nordlund, H. Zetterberg, 2010, Journal of Alzheimer's disease : JAD.

For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Definitions and Terminology Subcortical Ischaemic Vascular Dementia Subcortical Ischaemic Vascular Dementia Panel 1. Clinicopathological Classification of Vascular Dementia

H. Chui, L. Pantoni, T. Erkinjuntti, 2022 .